Analysis of adverse reactions in immunotherapy for 127 cases of non-small cell lung cancer
LI Feng
LIANG Yan
BIAN Yuan
FANG Qiang
ZHOU Jin
ZHOU Jun-xiang
WANG Yi-xin
Abstract：Objective:To analyze the occurrence characteristics and clinical manifestations of adverse reactions(ADR)of immunotherapy in 127 cases of non-small cell lung cancer(NSCLC),and to provide evidence for timely detection and control on the risks of drug safety.Methods:127 patients with NSCLC treated with immunotherapy from July 2019 to May 2023 were analyzed by gender and age,ADR-involved organs/systems and clinical manifestations,and ADR subgroups.Results:Among 127 patients,114 patients had ADR,of which 91 were male,accounting for 79.82％.ADR patients aged 60 to 74 years were the most common,accounting for 50 cases(43.86％).The most common ADR was digestive system and blood/lymphatic system damages,and nausea in 55 cases,vomiting in 53 cases,myelosuppression in 48 cases.Conclusion:There is a high probability of ADR events in NSCLC patients over 60 years old receiving immunotherapy,especially in the digestive system and the blood/lymphatic system.Since ADR of the blood/lymphatic system has a great impact on the therapeutic effect of the disease,the adverse reactions of the blood/lymphatic system should be monitored clinically.
Keywords：non-small cell lung cancerprogrammed death-1programmed death-ligand 1adverse reactionsanalysis and evaluationcomplex networkdrug safety
Publication Date：2024-08-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 1615-1620 )